Osteoporosis is a condition characterized by bone fragility, which reduces the skeleton's resistance to trauma and significantly increases the risk of fractures [8]. While often associated with aging, the foundation for strong bones is laid much earlier in life. Childhood and adolescence are critical periods for optimizing bone growth and mineral accrual, influencing bone strength throughout adulthood [7].
Bone strength is determined by several factors, including bone size, geometry, quality, and mass. These variables are influenced by genetics, physical activity, nutrition, and hormonal balance [7]. Understanding these factors is key to developing strategies for maintaining bone density and preventing osteoporosis.
Dietary and Lifestyle Factors for Bone Health
Nutrition plays a vital role in bone health, with certain elements being particularly important:
- Vitamin D: This vitamin is crucial for bone health, primarily by aiding in calcium absorption [4]. Studies indicate that mean serum vitamin D levels are often low in the general population, including those with thyroid conditions [1]. Furthermore, certain medications, such as carbamazepine, can significantly decrease vitamin D levels over time, potentially altering bone metabolism [3].
- Calcium: Adequate calcium intake is essential for bone mineral density (BMD). Research has shown that BMD and calcium levels can be significantly affected by different levels of iodine nutrition [2]. Impaired calcium absorption is also a known mechanism contributing to bone softening conditions like osteomalacia, often linked to certain medications [4].
- Iodine: While essential for thyroid function, excessive iodine intake may have negative implications for bone health. A study found that high urine and serum iodine concentrations were negatively correlated with BMD [2]. This suggests a need for balanced iodine nutrition, avoiding both deficiency and excess.
Medical Conditions Affecting Bone Density
Several underlying health conditions can increase the risk of osteoporosis:
- Thyroid Disease: Thyroid hormones naturally have a catabolic (bone-breaking) effect on bone homeostasis [1]. Patients with hyperthyroidism, for instance, have been observed to have higher levels of bone turnover markers and lower hip bone density compared to euthyroid (normal thyroid function) patients and healthy individuals [1]. This highlights the importance of managing thyroid conditions to protect bone health.
- Chronic Kidney Disease (CKD): Individuals with CKD face a particularly high risk of bone fragility and fractures. Bone issues in CKD are complex, resulting from a combination of primary osteoporosis, traditional risk factors, uremia-related factors, systemic disease impacts, and the detrimental effects of certain medications. Some of these risk factors are modifiable, offering potential targets for intervention [8].
Medications and Their Impact on Bones
Certain medications, especially with long-term use, can affect bone density and increase osteoporosis risk:
- Anticonvulsants: Long-term use of anticonvulsant medications, particularly enzyme-inducing agents like phenytoin, carbamazepine, and phenobarbital, is increasingly linked to adverse skeletal outcomes, including osteomalacia. Osteomalacia is characterized by defective bone mineralization, leading to bone softening, pain, muscle weakness, and a predisposition to fractures. The mechanisms involve disrupted vitamin D metabolism, impaired calcium absorption, and altered bone turnover [4]. Regular monitoring of bone health and potential supplementation are crucial for individuals on long-term antiepileptic treatment [4].
- Carbamazepine: Specifically, carbamazepine has been shown to significantly decrease serum vitamin D levels after treatment, indicating its potential to alter bone metabolism [3].
- Anti-CGRP Monoclonal Antibodies: In a positive finding, a prospective study evaluating anti-CGRP monoclonal antibody therapy for migraine found no early adverse effects on bone mineral density or bone turnover markers over a six-month period [6]. This suggests that this class of migraine medication appears safe for bone health in the short term.
- Romosozumab: For individuals with severe osteoporosis, particularly postmenopausal women and men at high risk of fracture, romosozumab is an approved anabolic treatment. Studies have shown it can significantly increase bone mineral density, with median increases of 6.7% at the lumbar spine, 2.9% at the total hip, and 2.3% at the femoral neck after 12 months of therapy. This efficacy was observed even in patients with diabetes or those who had previously received other antiresorptive therapies [5].
Building Strong Bones Throughout Life
Preventing osteoporosis is a lifelong endeavor, starting from childhood and continuing through adulthood. Optimizing bone growth and mineral accrual during formative years is paramount [7]. For adults, managing underlying health conditions like thyroid disease and chronic kidney disease is crucial for bone health [1, 8]. Individuals on medications known to affect bone metabolism, such as certain anticonvulsants, should undergo regular monitoring and discuss potential supplementation with their healthcare provider [4]. Addressing modifiable risk factors, including dietary choices and lifestyle habits, can significantly contribute to maintaining bone density and reducing fracture risk [8]. Always consult with a healthcare professional for personalized advice regarding bone health, prevention strategies, and treatment options.
Sources
- Comparison of Vitamin D Levels, Bone Metabolic Marker Levels, and Bone Mineral Density among Patients with Thyroid Disease: A Cross-Sectional Study. (Diagnostics (Basel, Switzerland), 2020)
- Relationships between iodine nutrition status, and bone mineral density and bone metabolism: a cross-sectional study of 1207 thyroid disease-free adults in China. (The British journal of nutrition, 2025)
- Long-term effects of carbamazepine on bone-related biochemical markers in patients with epilepsy. (Acta epileptologica, 2026)
- Navigating Bone Health in Epilepsy-A Detailed Review of Anticonvulsant-induced Osteomalacia: Its Mechanisms and Therapeutic Strategies. (The Journal of the Association of Physicians of India, 2026)
- Romosozumab Efficacy in Osteoporosis: Influence of Diabetes and Previous Antiresorptive Therapy: A Single Centre Experience. (Clinical medicine insights. Endocrinology and diabetes, 2026)
- Anti-CGRP monoclonal antibody therapy for migraine is not associated with early adverse bone effects: a prospective, observational, controlled, cohort study. (Frontiers in neurology, 2026)
- Consensus and controversy regarding osteoporosis in the pediatric population. (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2007)
- Traditional and Non-traditional Risk Factors for Osteoporosis in CKD. (Calcified tissue international, 2021)